SHR 1707
Alternative Names: SHR-1707Latest Information Update: 28 May 2024
At a glance
- Originator Atridia
- Developer Atridia; Shanghai Hengrui Pharmaceutical
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 28 May 2024 Phase I development is ongoing in Australia
- 28 Apr 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In volunteers, In adults) in Australia (IV, Infusion)
- 17 Apr 2024 Atridia initiates a Phase-I clinical trials in Alzheimer's disease in Australia (IV) (NCT06114745)